Key Takeaways
- Core domestic business resilient, up 8.6% with ~6% volume growth, the second high-single-digit quarter this fiscal, achieved despite urban demand headwinds and a delayed winter.
- BoroPlus antiseptic cream was the standout, growing over 20% on aggressive rural push and favorable dry weather, offsetting seasonal category weakness and lifting gross margins via mix.
- Kesh King remains the open wound: the brand needs another 4–5 months for a BCG-led strategy reset, and management admits the entire hair oil category has been struggling.
- Russia delivered its worst quarter in five years, a credit-cycle-driven aberration management expects to reverse in Q4; the 9-month cumulative performance is still double-digit growth.
- What to watch next quarter: whether the Smart and Handsome rebranding gains traction as new advertising scales, whether Russia rebounds as promised, and whether Kesh King’s strategy reset produces a concrete timeline.
Domestic Demand: Urban Drag, Rural Resilience
- Urban consumption stayed subdued, squeezed by food inflation and cash-strapped retail and wholesale trade; channel liquidity constraints have persisted since COVID with no timeline for improvement.
- Rural markets held up better, supported by favorable monsoons and a good harvest, which helped brands with deep rural distribution like BoroPlus.
- Delayed and mild winters hurt seasonal categories, yet BoroPlus still grew 20%, driven by the core antiseptic cream rather than winter-specific products.
- Channel credit cycles are stuck: management sees no room to reduce them and has no visibility on when the cash strap in trade will ease.
Mohan Goenka: "Credit cycles are very consistent, and at times, you may have to increase it. That's it. I don't know when it will improve, I have no idea."
Brand-Level Performance
| Brand / Segment | Trend | Commentary |
|---|---|---|
| BoroPlus | ▲ Strong | Antiseptic cream grew >20% on dry winter, aggressive advertising, focused rural push and changed trade schemes; momentum continued into January. |
| Healthcare range | ▲ Robust | Grew 13%, led by 90% growth in Zandu Care; health juices, cough syrup, Vigorex and ethical portfolio all delivered high double-digit growth. |
| Smart and Handsome (rebranded) | ▬ Transitioning | Rebranded from Fair and Handsome with Kartik Aaryan as new face; new advertising started 15 January; extensions into broader male grooming rolling out over next 3–4 months. |
| The Man Company | ▼ Soft | Hurt by compressed festive season, delayed shift to quick commerce, and urban consumption weakness; management transition complete, inventory normalized, Q4 expected significantly better. |
| Kesh King | ▼ Weak | Entire hair oil category struggling; BCG engaged to develop strategy; management asks for 4–5 months before a turnaround plan is firmed up. |
| Pancharishta | ▼ Declining | Post-COVID volume pressure across the Arishtha/Asava format; millennial acceptance a concern; new campaigns and modernized packaging in the works. |
- Zandu portfolio ex-Pancharishta is performing strongly across health juices, cough syrup, Vigorex, generics and the ethical medical business, where ayurvedic hospital coverage and doctor detailing have improved over the last 1.5 years.
- Smart and Handsome pricing unchanged during the rebranding; positioned as a mass product in ~15 lakh outlets, with HE serving the premium end.
Mohan Goenka: "I think it will take another one or two quarters, but then surely, we'll come with a bang."
International Business: A Russia Blip, Not a Trend
- Russia delivered a massive decline in Q3, the prime reason for international underperformance, driven by a very high inflation environment that prevented the business from extending normal 60–120 day credit into the market.
- Management calls it an aberration: over the last 5 years and 20 quarters, this is the only bad quarter; cumulatively for 9 months, Russia has still delivered double-digit growth.
- Other geographies expanded steadily: East Africa added certain products, GCC/MENA continued expanding Creme 21 and skincare portfolios, and Bangladesh attempted to extend the 7 Oils brand into shampoos with mixed response.
Mohan Goenka: "Almost in last 5 years, 20 quarters, there is 1 bad quarter due to very bad performance in Russia. We should have good revival in quarter 4. That's more an aberration which is happening."
Margins & Mix
- Gross margin expanded on three levers: price hikes and realization improvement (1.5%–2.5% on larger packs, not LUPs), input cost deflation mostly on packaging material, and cost reduction initiatives.
- Mix shift helped materially: BoroPlus antiseptic cream, a high-margin product, grew disproportionately and lifted the overall gross margin profile.
- Pricing was broad-based across the portfolio, applied to larger packs rather than low-unit packs.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Smart and Handsome range rollout | Entire male grooming range to start rolling out | Next 3–4 months |
| The Man Company recovery | Q4 expected to be significantly better than Q3 | Q4 FY25 |
| Russia revival | Good revival expected; Q3 decline called an aberration | Q4 FY25 |
| Kesh King strategy | BCG engagement underway; strategy to be firmed up | ~4–5 months |
| Overall growth trajectory | Expectation to do better than Q3; most brands on solid ground | Q4 FY25 |
| Pancharishta modernization | New campaigns and contemporary packaging being developed | No timeline given |
| Ethical portfolio insurance benefit | Gradual process; no dramatic change in short term | No timeline given |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated revenue | ₹1,049 cr, +5% YoY |
| Core domestic business growth | 8.6%, with volume growth of ~6% |
| Gross margin | 70.3%, expanded 150 bps YoY |
| EBITDA | ₹339 cr, +8% YoY; margin expanded 70 bps |
| Profit after tax | ₹279 cr, +8% YoY |
| 9M FY25 core domestic business growth | 7%, with volume growth of 5% |
| 9M FY25 EBITDA | ₹806 cr, +9% YoY |
| 9M FY25 PAT | ₹644 cr, +12% YoY |
| 9M FY25 operating cash flow | ₹500–550 cr (per an analyst's math) |
| Effective tax rate guidance | ~8–9% (FY25), ~10% (FY26) |
| Interim dividend | ₹4/share (400%), second interim; cumulative ₹8/share (800%) in FY24 |
| BoroPlus range growth | 20%, led by antiseptic cream |
| Healthcare range growth | 13%, led by 90% growth in Zandu Care |
| Male grooming decline | -4% |
| Kesh King decline | -10% |
| Navratna and Pain Management growth | 3% each |
| Strategic investments revenue decline | -13% |
| International business revenue decline | -3% |
| Organized channels contribution to domestic business | 28.6%, up 160 bps YoY |
| Rural salience of domestic business | 53–54% |
| CSD contribution | ~4% |
| The Man Company online/offline split | 75% online, 25% offline |
| Receivable cycle | 16–17 days, slightly improved YoY |
| Goodwill amortization guidance (FY26) | ~₹90 cr |